Skip to main content
. Author manuscript; available in PMC: 2017 Jul 1.
Published in final edited form as: Mult Scler Relat Disord. 2016 May 24;8:124–130. doi: 10.1016/j.msard.2016.05.015

Figure 1.

Figure 1

Annualized relapse rates (ARRs) in patient subgroups defined by demographic factors, treatment history, and disease characteristics at baseline (intent-to-treat population).

ARRs and ARR ratios for fingolimod 0.5 mg versus comparators were estimated using a negative binomial regression model adjusted for study. aARR was estimated using a negative binomial model with study as a factor. bTreatment-naïve patients were defined as those not receiving any drugs for the treatment of MS, according to MS history case-report forms. cARR was estimated using a negative binomial model, with study, treatment, subgroup, and treatment-by-subgroup as factors. CI, confidence interval; EDSS, Expanded Disability Status Scale; Gd, gadolinium; IFN, interferon; MS, multiple sclerosis